HOME >> BIOLOGY >> NEWS
Gene linked to cleft lip and palate identified

WHITE PLAINS, AUGUST 19, 2004 -- An international team of researchers has identified a gene variant that is a major contributor to oral clefts and triples the risk of recurrence in affected families, it was reported today in The New England Journal of Medicine.

"Cleft lip and cleft palate are among the most common birth defects in the United States," says Nancy S. Green, M.D., medical director of the March of Dimes, which helped fund the study. "This new finding brings us closer to understanding the multiple genetic factors underlying these very serious birth defects, with probable environmental effects."

The discovery also has important implications for genetic counseling for families who have had one or more children with an isolated cleft lip and/or cleft palate (not associated with any syndrome or other malformation), Dr. Green says.

"A special strength of this study is that its findings come from a variety of ethnic groups, including Europeans, South Americans, and Asians," Dr. Green says. "This gives us confidence that the linkage of this gene variant to oral clefts is true across different populations in the U.S. and worldwide."

The March of Dimes provided funding to Eduardo E. Castilla, M.D., Ph.D., Professor at ECLAMC, a genetic resource facility in Brazil, as well as to a collaboration between Andrew Lidral, D.D.S., Ph.D., Associate Professor, Department of Orthodontics, University of Iowa, Iowa City, and Mauricio Arcos-Burgos, M.D., Ph.D., at the University of Antioquia, Medellin, Colombia.

Cleft lip (with and without cleft palate) occurs in about 1 in every 1,000 births in the U.S., or more than 4,000 babies each year. A cleft is an opening or separation in a body structure. Clefts that occur in the oral-facial region often involve the upper lip, the roof of the mouth (hard palate), or the soft tissue in the back of the mouth (soft palate). More than 70 percent of babies with cleft lip also have cleft
'"/>

Contact: Michele Kling
mkling@marchofdimes.com
914-997-4613
March of Dimes Birth Defects Foundation
18-Aug-2004


Page: 1 2

Related biology news :

1. Genetic mutations linked to the practice of burning coal in homes in China
2. Enzyme maintaining chromosome ends is linked to bone cancer recurrence, decreased survival
3. Protein involved in childhood disorder linked to cancer
4. Mouse study shows NPAS3 and NPAS1 genes may be linked to psychosis
5. Schizophrenia gene variant linked to risk traits
6. Gene changes linked to increased eye pressure may have implications for glaucoma therapy
7. Excess levels of nitrogen, phosphorus linked to deformed frogs
8. Genetic mutation linked to more aggressive breast cancer found more often in African-Americans
9. LBP-1a gene mutation linked to disruption of normal fetal development
10. Outcome for acute lymphoblastic leukemia linked to gene expression patterns
11. UCI study reveals gene linked to breast cancer can suppress tumors

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gene linked cleft lip and palate identified

(Date:3/23/2015)... LOS ANGELES , March 23, 2015  In ... in Federal fraud case conviction losses. This figure accounts ... fraud, which, according to The Nilson Report, exceeds $11 ... an investigative tool after a crime has occurred. Investor ... Agent and polygraph expert Joe Paolella partnered ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report ... markets for Iris Biometrics in US$ Thousands. The report provides ... , Japan , Europe ... , and Latin America . ...
(Date:3/17/2015)...  MecklerMedia Corporation (OTCQX: MECK) announced its ... ever held in New York City ... 2015 at the Javits Convention Center. ... Acorn Product Development; Axis NJ; c-Link Systems; CoroWare; ... NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; RocketFarm ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
(Date:3/30/2015)... 2015 CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , announced ... has approved the Company,s application to conduct a Phase ... (OCCC) patients for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... CARDIFF, UK, and BELLINGHAM, Washington, USA (PRWEB) March 29, ... energy projects in Europe and the United States and ... programme highlights planned for SPIE Optics + Optoelectronics ... will feature over 700 technical presentations in 17 conferences ... international society for optics and photonics , the event ...
(Date:3/30/2015)... MADISON, Wis. , March 30, 2015  FUJIFILM ... ("Fujifilm") and Cellular Dynamics International, Inc. (CEO: Robert ... leading developer and manufacturer of fully functioning human cells ... the two companies have entered into a definitive agreement ... offer to be followed by a second step merger. ...
(Date:3/29/2015)... March 29, 2015 As a symbol ... required by our pharmaceutical manufacturing clients, Whitehouse Laboratories is ... of the Berkenstock Race Team for the 2015 race ... only speed, but a strong sense of precision and ... lead to success in the quality control testing laboratory. ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2
Cached News: